New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.
Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of EGFR mutations confirmed he had a sensitive mutation (exon 19 deletion). This case supports that icotinib has great efficacy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yulong
Y
Zheng
Weijia
W
Fang
Xiao
X
Liu
Nong
N
Xu
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D043844:Crown Ethers / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D005091:Exons; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043844:Crown Ethers; D004791:Enzyme Inhibitors; D011799:Quinazolines; C531470:icotinib; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases